Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement
Bibliographic Data
| ID | 14908016 |
|---|---|
| Authors | Alexander F Infante (0009-0002-0749-486X, University of Illinois Chicago, corresponding author), Abigail T Elmes (0000-0002-0964-2574, University of Illinois Chicago), Renee Petzel Gimbar (0000-0001-5021-6932, University of Illinois Chicago), Sarah Messmer (0000-0001-9509-3219, University of Illinois Urbana-Champaign), Sarah E Messmer, Christine Neeb (0009-0007-0226-6602, University of Colorado Denver), Jennie B Jarrett (0000-0003-0583-308X, University of Illinois Chicago) |
| Year | 2024 |
| Volume | 124 |
| Pages | 104323 |
| Publication date | 2024-02-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2024.104323 |
| PMID | 38232438 |
| OpenAlex | W4390900875 |
| Language | EN |
| Citations received | 2 |
| References cited | 14 |
The fatal overdose crisis claims nearly 200 lives daily in the United States (U.S). Evolutions in the illicit drug supply, such as the addition of sedative adulterants and a shift to synthetic opioids such as fentanyl, have driven increasing rates of both fatal and non-fatal overdose. Specifically, synthetic opioid usage of fentanyl was implicated in 68 % of the U.S. drug overdose deaths in 2022 alone. This has placed tremendous burden on communities, emergency medical services, and healthcare systems, and contributed to tragedy and grief both in the U.S. and worldwide. Despite the availability of effective opioid antagonist medications and standards of care, there has been increased interest in research and development of alternative opioid overdose reversal agents by the National Institutes of Health (NIH) in partnership with pharmaceutical manufacturers over the last decade. The U.S. Food and Drug Administration (FDA) recently approved nalmefene (Opvee) a mu-opioid receptor antagonist that boasts an extended half-life and stronger mu-receptor affinity compared to the standard of care use of naloxone for opioid reversal. In this article, we explore the medical need and ramifications of the introduction of longer-acting opioid antagonists in the current opioid overdose landscape. Existing data highlight the effectiveness of already available naloxone products as a safe and effective standard of care. These data support the notion that stronger, longer-acting agents may be unnecessary, and their existence may cause undue harm, such as more severe and/or prolonged withdrawal symptoms, lead to challenging patient interactions, and complicate the initiation of medications for opioid use disorder. More evidence is needed before healthcare professionals should implement the use of stronger, longer-acting opioid antagonists for reversing opioid overdose over evidence-based, cost-effective naloxone
Fentanyl · Intensive care medicine · Nalmefene · Naltrexone · Opioid · Opioid antagonist · Opioid overdose · Medicine · Opioid Use Disorder Treatment · Pain Management and Opioid Use · Poisoning and overdose treatments · Internal Medicine · Pharmacology
| Citations per year | 1 |
|---|---|
| Citation span | 2024 - 2025 (2) |
| Highly cited | No |